• A novel immune checkpoint inhibitor antibody, following the strategy of Keytruda®, Opdivo® and Tecentriq®
  • BP1210 enhances anti-tumor immunity by inhibiting the suppression of cytotoxic T cells


BP1210 is an innovative antibody drug that blocks the function of an immune checkpoint receptor called TIM-3, following PD-1 and PD-L1 inhibitors that are immune checkpoint inhibitors on track for regulatory approvals across multiple cancer types or stages worldwide.

BP1210 is a humanized, anti-TIM-3 antibody designed to bind simultaneously to two distinct domains of TIM-3. TIM-3 has multiple ligands, including phosphatidylserine (PS) and galectin-9 (Gal-9), which bind to different regions and distinctively deactivate the function of immune cells involved in tumor immunity. However, anti-TIM-3 antibodies so far in clinical development are only able to interfere with PS binding, but not Gal-9 binding.

BP1210 is an Fc-engineered, biparatopic antibody designed to block the interaction of the multiple ligands on TIM-3. Bivalent binding to a single molecule of TIM-3 also confers high affinity and specificity to the antibody's target, thereby allowing BP1210 to effectively abrogate the suppression of T cell cytotoxicity. BP1210 in combination with other suppressive immune pathways such as PD-1/PD-L1, is a key strategy to enhance the anti-tumor cytotoxic potential of immunotherapy.

Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity

SITC 2021


Page Top